[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Trifluoperazine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Trifluoperazine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Trifluoperazine.]
[N05AL01, sulpiride, Trifluoperazine may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Trifluoperazine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Azapropazone.]
[N06DA01, tacrine, The metabolism of Trifluoperazine can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Trifluoperazine can be decreased when combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Trifluoperazine.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Trifluoperazine.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Trifluoperazine.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetracaine.]
[N05AE05, lurasidone, Trifluoperazine may increase the hypotensive activities of Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Trifluoperazine.]
[L04AX02, thalidomide, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Trifluoperazine.]
[R03DA04, theophylline, The metabolism of Trifluoperazine can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Trifluoperazine can be decreased when combined with Thiabendazole.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trifluoperazine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopental.]
[N05AB08, thioproperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Trifluoperazine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Tilidine.]
[S01ED01, timolol, The serum concentration of Timolol can be increased when it is combined with Trifluoperazine.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Trifluoperazine.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Trifluoperazine.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Trifluoperazine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Trifluoperazine is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Trifluoperazine.]
[N06AX05, trazodone, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[C03DB02, triamterene, The metabolism of Trifluoperazine can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triazolam.]
[C03AA06, trichlormethiazide, Trifluoperazine may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Trifluoperazine.]
[A03AA05, trimebutine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Trimethadione.]
[C02BA01, trimethaphan, Trifluoperazine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Trifluoperazine.]
[A03BB01, butylscopolamine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Trifluoperazine.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Trifluoperazine.]
[C09CA09, azilsartan medoxomil, Trifluoperazine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tubocurarine.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Trifluoperazine.]
[L02BX03, abiraterone, The serum concentration of Trifluoperazine can be increased when it is combined with Abiraterone.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ezogabine.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Trifluoperazine.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N06AX09, viloxazine, The metabolism of Trifluoperazine can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Trifluoperazine may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Trifluoperazine.]
[B01AA03, warfarin, The metabolism of Trifluoperazine can be decreased when combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Xenon.]
[C03BA10, xipamide, Trifluoperazine may decrease the antihypertensive activities of Xipamide.]
[J01MB04, pipemidic acid, The metabolism of Trifluoperazine can be decreased when combined with Pipemidic acid.]
[N05AF05, zuclopenthixol, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The serum concentration of Trifluoperazine can be increased when it is combined with Vemurafenib.]
[J01MA13, trovafloxacin, The metabolism of Trifluoperazine can be decreased when combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Trifluoperazine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Trifluoperazine can be decreased when combined with Peginterferon alfa-2a.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Atracurium.]
[S01FA01, atropine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Trifluoperazine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Trifluoperazine.]
[G04BE10, avanafil, Trifluoperazine may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Trifluoperazine.]
[G04BD12, mirabegron, The therapeutic efficacy of Mirabegron can be decreased when used in combination with Trifluoperazine.]
[L04AA31, teriflunomide, The serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Trifluoperazine.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Trifluoperazine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Trifluoperazine.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trifluoperazine.]
[R06AC06, thonzylamine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diethyl ether.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Trifluoperazine.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, Trifluoperazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benperidol.]
[J01MA15, gemifloxacin, The metabolism of Trifluoperazine can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Trifluoperazine can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Trifluoperazine can be decreased when combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Trifluoperazine.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzocaine.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Trifluoperazine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluoperazine.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Bepridil.]
[C02KX05, riociguat, Trifluoperazine may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Trifluoperazine may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Trifluoperazine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Trifluoperazine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Trifluoperazine can be decreased when combined with Dapagliflozin.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Trifluoperazine.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Trifluoperazine.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Trifluoperazine can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Trifluoperazine.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Trifluoperazine.]
[L04AC11, siltuximab, The metabolism of Trifluoperazine can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, Trifluoperazine may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Trifluoperazine.]
[L01XH04, belinostat, The metabolism of Trifluoperazine can be increased when combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Trifluoperazine can be decreased when combined with Idelalisib.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alfaxalone.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Trifluoperazine.]
[D11AA01, glycopyrronium, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[A06AH03, naloxegol, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Naloxegol.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Trifluoperazine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Trifluoperazine.]
[N06AX11, mirtazapine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Trifluoperazine can be increased when combined with Secukinumab.]
[N02BE01, acetaminophen, The metabolism of Trifluoperazine can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Trifluoperazine.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Trifluoperazine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Acetophenazine.]
[L01EB04, osimertinib, The serum concentration of Trifluoperazine can be decreased when it is combined with Osimertinib.]
[B01AC27, selexipag, Trifluoperazine may decrease the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Trifluoperazine.]
[G04CA01, alfuzosin, Trifluoperazine may increase the hypotensive activities of Alfuzosin.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Alminoprofen.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.]
[N04BC01, bromocriptine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trifluoperazine.]
[N06AA19, amineptin, The serum concentration of Amineptine can be increased when it is combined with Trifluoperazine.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Amlodipine.]
[N05AX17, pimavanserin, Trifluoperazine may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Trifluoperazine can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluoperazine.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Trifluoperazine.]
[N07BC01, buprenorphine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Trifluoperazine.]
[P01BE03, artesunate, The risk or severity of QTc prolongation can be increased when Artesunate is combined with Trifluoperazine.]
[N02AF01, butorphanol, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Butorphanol.]
[S01GX07, azelastine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Trifluoperazine can be increased when combined with Rucaparib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Trifluoperazine.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Trifluoperazine.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Trifluoperazine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Trifluoperazine can be decreased when combined with Caffeine.]
[C09AA07, benazepril, Trifluoperazine may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XX08, linezolid, The risk or severity of extrapyramidal symptoms can be increased when Linezolid is combined with Trifluoperazine.]
[L04AB02, infliximab, The metabolism of Trifluoperazine can be increased when combined with Infliximab.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be decreased when used in combination with Trifluoperazine.]
[L01XX59, enasidenib, The metabolism of Trifluoperazine can be decreased when combined with Enasidenib.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Trifluoperazine.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Trifluoperazine.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Trifluoperazine.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Trifluoperazine.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Trifluoperazine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brotizolam.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Trifluoperazine.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butobarbital.]
[N06AA15, butriptyline, The serum concentration of Butriptyline can be increased when it is combined with Trifluoperazine.]
[N01BX04, capsaicin, The metabolism of Trifluoperazine can be increased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vinylbital.]
[C09AA01, captopril, Trifluoperazine may decrease the antihypertensive activities of Captopril.]
[N03AF01, carbamazepine, The metabolism of Trifluoperazine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Trifluoperazine.]
[L03AB06, interferon alfa-n1, The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Trifluoperazine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Trifluoperazine.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Trifluoperazine.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Trifluoperazine.]
[P01BA07, tafenoquine, The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Trifluoperazine.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Trifluoperazine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carbromal.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Trifluoperazine.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Trifluoperazine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Trifluoperazine.]
[R03BB08, revefenacin, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Trifluoperazine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Trifluoperazine can be decreased when combined with Carmustine.]
[C09AA08, cilazapril, Trifluoperazine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Trifluoperazine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Trifluoperazine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Trifluoperazine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Trifluoperazine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Trifluoperazine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cloxazolam.]
[C09CA06, candesartan, Trifluoperazine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Trifluoperazine can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyamemazine.]
[C03BX03, cicletanine, Trifluoperazine may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Trifluoperazine.]
[N07XX11, pitolisant, The metabolism of Trifluoperazine can be increased when combined with Pitolisant.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Trifluoperazine.]
[C03AA09, cyclothiazide, Trifluoperazine may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Trifluoperazine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Trifluoperazine.]
[A16AX16, givosiran, The serum concentration of Trifluoperazine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trifluoperazine.]
[N02AX03, dezocine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Trifluoperazine.]
[M01AX21, diacetylrhein, The metabolism of Trifluoperazine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Trifluoperazine can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Trifluoperazine can be decreased when combined with Osilodrostat.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Trifluoperazine.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Trifluoperazine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Trifluoperazine.]
[M01AH02, rofecoxib, The metabolism of Trifluoperazine can be decreased when combined with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Clevidipine.]
[C01BD07, dronedarone, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trifluoperazine.]
[C02AA06, methoserpidine, Trifluoperazine may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Trifluoperazine can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Trifluoperazine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Trifluoperazine.]
[P01BE01, artemisinin, The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Trifluoperazine.]
[G04BD09, trospium, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Levamlodipine.]
[P01BB01, proguanil, The risk or severity of QTc prolongation can be increased when Proguanil is combined with Trifluoperazine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Trifluoperazine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Trifluoperazine is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Trifluoperazine.]
[C03AA04, chlorothiazide, Trifluoperazine may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Trifluoperazine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trifluoperazine.]
[N05AF03, chlorprothixene, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Trifluoperazine may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trifluoperazine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Trifluoperazine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Etofenamate.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Trifluoperazine can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Trifluoperazine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Fenbufen.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Trifluoperazine.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Trifluoperazine.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Finasteride.]
[J01MB07, flumequine, The metabolism of Trifluoperazine can be decreased when combined with Flumequine.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Trifluoperazine.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Trifluoperazine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Trifluoperazine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Trifluoperazine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Trifluoperazine can be decreased when combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The metabolism of Trifluoperazine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Trifluoperazine can be increased when combined with Somapacitan.]
[P01CA03, fexinidazole, The metabolism of Trifluoperazine can be decreased when combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Trifluoperazine can be increased when combined with Lonapegsomatropin.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Trifluoperazine.]
[M01AG01, mefenamic acid, The metabolism of Trifluoperazine can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Trifluoperazine.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Trifluoperazine.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Trifluoperazine.]
[J01FF01, clindamycin, Trifluoperazine may increase the neurotoxic activities of Clindamycin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Trifluoperazine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Trifluoperazine can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of desmethylclomipramine, an active metabolite of Clomipramine, can be increased when used in combination with Trifluoperazine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Trifluoperazine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Granisetron.]
[N05AH02, clozapine, Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Trifluoperazine.]
[H01AC08, somatrogon, The metabolism of Trifluoperazine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Trifluoperazine.]
[L04AC21, bimekizumab, The metabolism of Trifluoperazine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexafluronium.]
[A03AB10, hexocyclium, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Trifluoperazine can be decreased when it is combined with Leflunomide.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tropisetron.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Trifluoperazine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Imidazole salicylate.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Trifluoperazine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Trifluoperazine.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Trifluoperazine.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluoperazine.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Parecoxib.]
[S01AD03, acyclovir, The metabolism of Trifluoperazine can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Kebuzone.]
[L01EA01, imatinib, The metabolism of Trifluoperazine can be decreased when combined with Imatinib.]
[C08CA09, lacidipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Lacidipine.]
[N03AX09, lamotrigine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Trifluoperazine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Lomefloxacin can be decreased when combined with Trifluoperazine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Loxoprofen.]
[C09AA03, lisinopril, Trifluoperazine may decrease the antihypertensive activities of Lisinopril.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Manidipine.]
[A03AA04, mebeverine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Mefenorex.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Trifluoperazine.]
[R06AD07, mequitazine, Trifluoperazine may increase the arrhythmogenic activities of Mequitazine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Trifluoperazine.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Trifluoperazine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melperone.]
[C03AA07, cyclopenthiazide, Trifluoperazine may decrease the antihypertensive activities of Cyclopenthiazide.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Trifluoperazine.]
[N06AX07, minaprine, The risk or severity of extrapyramidal symptoms can be increased when Minaprine is combined with Trifluoperazine.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Trifluoperazine.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Trifluoperazine.]
[N06AG02, moclobemide, The risk or severity of extrapyramidal symptoms can be increased when Moclobemide is combined with Trifluoperazine.]
[N06BA07, modafinil, The metabolism of Trifluoperazine can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Trifluoperazine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Morniflumate.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Trifluoperazine.]
[J05AF10, entecavir, The metabolism of Trifluoperazine can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Trifluoperazine.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Trifluoperazine.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Trifluoperazine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of QTc prolongation can be increased when Dapsone is combined with Trifluoperazine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Deanol.]
[C02CC04, debrisoquin, Trifluoperazine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[M01AX01, nabumetone, The metabolism of Trifluoperazine can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nordazepam.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Trifluoperazine.]
[N06AX06, nefazodone, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Niaprazine.]
[C01DX16, nicorandil, Trifluoperazine may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Trifluoperazine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Trifluoperazine.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Trifluoperazine.]
[R05DA06, normethadone, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Escitalopram.]
[G04BD08, solifenacin, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Olsalazine.]
[N06AA01, desipramine, The serum concentration of Desipramine can be increased when it is combined with Trifluoperazine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Trifluoperazine.]
[C09XA02, aliskiren, Trifluoperazine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Trifluoperazine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Trifluoperazine.]
[G04BD04, oxybutynin, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Trifluoperazine.]
[A03AA01, oxyphencyclimine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Trifluoperazine can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trifluoperazine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Trifluoperazine.]
[N02AC01, dextromoramide, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Trifluoperazine can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Trifluoperazine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Trifluoperazine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenacemide.]
[V03AH01, diazoxide, Trifluoperazine may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phensuximide.]
[N06AA08, dibenzepin, The serum concentration of Dibenzepin can be increased when it is combined with Trifluoperazine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Trifluoperazine.]
[S01BC03, diclofenac, The metabolism of Trifluoperazine can be decreased when combined with Diclofenac.]
[A03AA07, dicyclomine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Trifluoperazine may increase the neurotoxic activities of Didanosine.]
[C02DG01, pinacidil, Trifluoperazine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipamperone.]
[A03AB14, pipenzolate, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Trifluoperazine can be decreased when combined with Erlotinib.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Trifluoperazine.]
[A08AA03, diethylpropion, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Isradipine.]
[A03AB11, poldine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Diflunisal.]
[C02DB01, dihydralazine, The metabolism of Trifluoperazine can be decreased when combined with Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N02AA03, hydromorphone, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Trifluoperazine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Trifluoperazine may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pridinol.]
[R06AB03, dimethindene, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Trifluoperazine.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Trifluoperazine.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Trifluoperazine.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Proglumetacin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Trifluoperazine.]
[R06AA02, diphenhydramine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quazepam.]
[C09AA06, quinapril, Trifluoperazine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Trifluoperazine.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The serum concentration of Quinupramine can be increased when it is combined with Trifluoperazine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Trifluoperazine.]
[C09AA05, ramipril, Trifluoperazine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluoperazine.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Trifluoperazine.]
[C01BA03, disopyramide, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Trifluoperazine can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Trifluoperazine.]
[N05AX08, risperidone, Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine.]
[J01MB01, rosoxacin, The metabolism of Trifluoperazine can be decreased when combined with Rosoxacin.]
[L01XG01, bortezomib, The metabolism of Trifluoperazine can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Trifluoperazine.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Trifluoperazine.]
[C02KX02, ambrisentan, Trifluoperazine may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Salsalate.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Trifluoperazine.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Trifluoperazine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Trifluoperazine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Dopamine.]
[N06AA16, dothiepin, The serum concentration of Dosulepin can be increased when it is combined with Trifluoperazine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Trifluoperazine.]
[N06AA12, doxepin, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sibutramine.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C09AA11, spirapril, Trifluoperazine may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Trifluoperazine.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Trifluoperazine.]
[J01MA05, temafloxacin, The metabolism of Trifluoperazine can be decreased when combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Trifluoperazine.]
[G04CA03, terazosin, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Trifluoperazine.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Terodiline.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Trifluoperazine.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Trifluoperazine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopropazate.]
[G04BD01, emepronium, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Trifluoperazine.]
[C09AA02, enalapril, Trifluoperazine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of extrapyramidal symptoms can be increased when Toloxatone is combined with Trifluoperazine.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Trifluoperazine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Trifluoperazine.]
[C03CA04, torsemide, Trifluoperazine may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Tramazoline.]
[C09AA10, trandolapril, Trifluoperazine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triclofos.]
[A03AB08, tridihexethyl, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Trifluoperazine.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Trifluoperazine.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Trifluoperazine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Trifluoperazine.]
[C02CA06, urapidil, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The metabolism of Trifluoperazine can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Veralipride.]
[L01CA04, vinorelbine, Vinorelbine may increase the neurotoxic activities of Trifluoperazine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Trifluoperazine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Trifluoperazine.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Trifluoperazine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Trifluoperazine.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Trifluoperazine.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Trifluoperazine.]
[C09AA15, zofenopril, Trifluoperazine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Trifluoperazine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zotepine.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Trifluoperazine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Trifluoperazine.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Trifluoperazine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.]
[N02CA02, ergotamine, Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trifluoperazine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Estazolam.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Trifluoperazine.]
[G03CA03, estradiol, The metabolism of Trifluoperazine can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Trifluoperazine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Trifluoperazine can be decreased when combined with Ethambutol.]
[C01CA15, gepefrine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluoperazine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Trifluoperazine.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Trifluoperazine.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Trifluoperazine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Trifluoperazine.]
[S01XA06, ethylmorphine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Trifluoperazine.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Trifluoperazine.]
[L01CB01, etoposide, The metabolism of Trifluoperazine can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertindole.]
[R06AX12, terfenadine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Trifluoperazine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Trifluoperazine.]
[A02BA03, famotidine, The metabolism of Trifluoperazine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Trifluoperazine can be increased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Trifluoperazine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Trifluoperazine.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Trifluoperazine.]
[N02AB03, fentanyl, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Fentanyl.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Trifluoperazine.]
[G04BD02, flavoxate, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Trifluoperazine.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Floctafenine.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunitrazepam.]
[N06AA14, melitracen, The serum concentration of Melitracen can be increased when it is combined with Trifluoperazine.]
[V03AZ01, ethanol, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Trifluoperazine can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Trifluoperazine.]
[N05AG01, fluspirilene, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Trifluoperazine can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Trifluoperazine.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Trifluoperazine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of extrapyramidal symptoms can be increased when Furazolidone is combined with Trifluoperazine.]
[C03CA01, furosemide, Trifluoperazine may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Trifluoperazine is combined with Eszopiclone.]
[N05AL05, amisulpride, Trifluoperazine may increase the antipsychotic activities of Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Trifluoperazine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Trifluoperazine.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Trifluoperazine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Trifluoperazine.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Trifluoperazine.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Trifluoperazine.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Trifluoperazine.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Trifluoperazine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Glutethimide.]
[C05AE01, nitroglycerin, Trifluoperazine may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[L01EX02, sorafenib, The metabolism of Trifluoperazine can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Trifluoperazine.]
[C09AA09, fosinopril, Trifluoperazine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Trifluoperazine may decrease the antihypertensive activities of Guanethidine.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Trifluoperazine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Trifluoperazine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.]
[N05AH04, quetiapine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Trifluoperazine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Allobarbital.]
[C09CA01, losartan, Trifluoperazine may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Trifluoperazine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexobarbital.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Trifluoperazine.]
[J05AG01, nevirapine, The metabolism of Trifluoperazine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nimesulide.]
[C09AA04, perindopril, Trifluoperazine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Trifluoperazine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Trifluoperazine may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Trifluoperazine may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Trifluoperazine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Trifluoperazine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Ibuprofen.]
[B05CB02, sodium citrate, Trifluoperazine may increase the neurotoxic activities of Sodium citrate.]
[H01AC02, somatrem, The metabolism of Trifluoperazine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[L01CD01, paclitaxel, Trifluoperazine may increase the neurotoxic activities of Paclitaxel.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Trifluoperazine.]
[C03BA11, indapamide, Trifluoperazine may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Trifluoperazine.]
[C02CA02, indoramin, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[L03AB04, interferon alfa-2a, The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Trifluoperazine can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Milnacipran.]
[A03AA30, piperidolate, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluoperazine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon.]
[R06AE01, buclizine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The metabolism of Trifluoperazine can be decreased when combined with Anagrelide.]
[C07AA01, alprenolol, The serum concentration of Alprenolol can be increased when it is combined with Trifluoperazine.]
[L03AB09, interferon alfacon-1, The metabolism of Trifluoperazine can be decreased when combined with Interferon alfacon-1.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Trifluoperazine.]
[N06AA13, iprindole, The serum concentration of Iprindole can be increased when it is combined with Trifluoperazine.]
[N06AF05, iproniazid, The risk or severity of extrapyramidal symptoms can be increased when Iproniazid is combined with Trifluoperazine.]
[J05AB13, penciclovir, The metabolism of Trifluoperazine can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of extrapyramidal symptoms can be increased when Isocarboxazid is combined with Trifluoperazine.]
[P01AX06, atovaquone, The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Trifluoperazine.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Trifluoperazine.]
[C09AA16, imidapril, Trifluoperazine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Trifluoperazine.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be decreased when used in combination with Trifluoperazine.]
[J04AC01, isoniazid, The metabolism of Trifluoperazine can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Trifluoperazine.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Trifluoperazine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Trifluoperazine.]
[H01AC01, somatropin, The metabolism of Trifluoperazine can be increased when combined with Somatotropin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Trifluoperazine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Trifluoperazine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Trifluoperazine can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Trifluoperazine.]
[N04BC09, rotigotine, Trifluoperazine may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The metabolism of Trifluoperazine can be decreased when combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Trifluoperazine.]
[C02AA05, deserpidine, Trifluoperazine may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lacosamide.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Trifluoperazine.]
[S02DA01, lidocaine, The metabolism of Trifluoperazine can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Lidoflazine.]
[J01FF02, lincomycin, Trifluoperazine may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Trifluoperazine can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Trifluoperazine.]
[N06AA07, lofepramine, The serum concentration of Lofepramine can be increased when it is combined with Trifluoperazine.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluoperazine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Trifluoperazine can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Trifluoperazine.]
[C02BB01, mecamylamine, Trifluoperazine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Trifluoperazine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Trifluoperazine.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melatonin.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Trifluoperazine.]
[N02AB02, meperidine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Meperidine.]
[C01CA11, mephentermine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Trifluoperazine.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.]
[N02AX05, meptazinol, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.]
[N05AX13, paliperidone, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Trifluoperazine.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Trifluoperazine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.]
[N06BA03, methamphetamine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Trifluoperazine.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Trifluoperazine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Trifluoperazine can be decreased when combined with Pemetrexed.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Trifluoperazine.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Trifluoperazine.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Trifluoperazine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Trifluoperazine.]
[D05BA02, methoxsalen, The metabolism of Trifluoperazine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methoxyflurane.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Trifluoperazine.]
[V04CG05, methylene blue, The risk or severity of extrapyramidal symptoms can be increased when Methylene blue is combined with Trifluoperazine.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Trifluoperazine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Trifluoperazine.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Trifluoperazine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Trifluoperazine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.]
[C03BA08, metolazone, Trifluoperazine may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The serum concentration of Metoprolol can be increased when it is combined with Trifluoperazine.]
[C01BB02, mexiletine, The metabolism of Trifluoperazine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Trifluoperazine.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Trifluoperazine.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Trifluoperazine.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Trifluoperazine.]
[C09CA03, valsartan, Trifluoperazine may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[D11AX01, minoxidil, Trifluoperazine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Trifluoperazine can be decreased when combined with Amiodarone.]
[N02AA01, morphine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Trifluoperazine.]
[L04AB05, certolizumab pegol, The metabolism of Trifluoperazine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Trifluoperazine.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Trifluoperazine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Trifluoperazine.]
[G04CA04, silodosin, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[R03BB01, ipratropium bromide, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be increased when it is combined with Trifluoperazine.]
[L03AB08, interferon beta-1b, The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Trifluoperazine.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Trifluoperazine.]
[J01CF06, nafcillin, The metabolism of Trifluoperazine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Trifluoperazine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Trifluoperazine.]
[N06BA01, amphetamine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The metabolism of Trifluoperazine can be decreased when combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Duloxetine.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be decreased when used in combination with Trifluoperazine.]
[S03AA01, neomycin, Trifluoperazine may increase the neurotoxic activities of Neomycin.]
[N01AH06, remifentanil, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Remifentanil.]
[N05AX14, iloperidone, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Trifluoperazine may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of extrapyramidal symptoms can be increased when Nialamide is combined with Trifluoperazine.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[P02DA01, niclosamide, The metabolism of Trifluoperazine can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Trifluoperazine.]
[C02DD01, nitroprusside, Trifluoperazine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nomifensine.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Trifluoperazine.]
[S01AE02, norfloxacin, The metabolism of Trifluoperazine can be decreased when combined with Norfloxacin.]
[C02KX01, bosentan, Trifluoperazine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[L03AB07, interferon beta-1a, The metabolism of Trifluoperazine can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Trifluoperazine.]
[L04AC04, rilonacept, The metabolism of Trifluoperazine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Trifluoperazine can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The serum concentration of Opipramol can be increased when it is combined with Trifluoperazine.]
[N02AA02, opium, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Opium.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Trifluoperazine.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Trifluoperazine.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxazepam.]
[C07AA02, oxprenolol, The serum concentration of Oxprenolol can be increased when it is combined with Trifluoperazine.]
[N02AA05, oxycodone, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Oxycodone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Trifluoperazine.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trifluoperazine.]
[N02AA11, oxymorphone, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[M03AC01, pancuronium, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of extrapyramidal symptoms can be increased when Pargyline is combined with Trifluoperazine.]
[J01MA03, pefloxacin, The metabolism of Trifluoperazine can be decreased when combined with Pefloxacin.]
[G04BD11, fesoterodine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The serum concentration of Penbutolol can be increased when it is combined with Trifluoperazine.]
[N05AG03, penfluridol, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Trifluoperazine.]
[C04AD03, pentoxifylline, The metabolism of Trifluoperazine can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Trifluoperazine.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Trifluoperazine.]
[N02AD02, phenazocine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of extrapyramidal symptoms can be increased when Phenelzine is combined with Trifluoperazine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Trifluoperazine.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Trifluoperazine.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Trifluoperazine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Trifluoperazine.]
[L04AB06, golimumab, The metabolism of Trifluoperazine can be increased when combined with Golimumab.]
[C08CX01, mibefradil, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pimozide.]
[C07AA03, pindolol, The serum concentration of Pindolol can be increased when it is combined with Trifluoperazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipotiazine.]
[C09CA02, eprosartan, Trifluoperazine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Trifluoperazine.]
[N02AC03, pirinitramide, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Trifluoperazine.]
[J01MA11, grepafloxacin, The metabolism of Trifluoperazine can be decreased when combined with Grepafloxacin.]
[N02CX01, pizotyline, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[C09CA04, irbesartan, Trifluoperazine may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Proxibarbal.]
[A03AE01, alosetron, The metabolism of Trifluoperazine can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Trifluoperazine can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Trifluoperazine may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Trifluoperazine may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Trifluoperazine can be increased when combined with Ritonavir.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Trifluoperazine.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Trifluoperazine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Trifluoperazine.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Trifluoperazine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Trifluoperazine.]
[N03AA03, primidone, The metabolism of Trifluoperazine can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of extrapyramidal symptoms can be increased when Procaine is combined with Trifluoperazine.]
[L01XB01, procarbazine, The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Trifluoperazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Trifluoperazine.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[R06AD02, promethazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Trifluoperazine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Propanidid.]
[A03AB05, propantheline, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.]
[N02AC04, propoxyphene, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Trifluoperazine.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Trifluoperazine.]
[B01AC09, epoprostenol, Trifluoperazine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The serum concentration of Protriptyline can be increased when it is combined with Trifluoperazine.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[A03AB15, diphemanil, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[S01FA03, methscopolamine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Trifluoperazine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepyramine.]
[P01BD01, pyrimethamine, The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Trifluoperazine.]
[P01AX05, quinacrine, The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Trifluoperazine.]
[C01BA01, quinidine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Trifluoperazine.]
[A02BA02, ranitidine, The metabolism of Ranitidine can be decreased when combined with Trifluoperazine.]
[C02AA01, rescinnamine, Trifluoperazine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Trifluoperazine.]
[J04AB02, rifampin, The metabolism of Trifluoperazine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Trifluoperazine.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Trifluoperazine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Trifluoperazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Trifluoperazine is combined with Salicylic acid.]
[S01FA02, scopolamine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be decreased when used in combination with Trifluoperazine.]
[C07AA07, sotalol, The serum concentration of Sotalol can be increased when it is combined with Trifluoperazine.]
